MT. KISCO N.Y., Jan. 26, 2015 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that It has chosen HellaWella as a media partner. The first published content can be accessed here:
ImmuDyne will be providing additional content in the near future, all of which will run in HellaWella's e-newsletters to approximately 100,000 readers), and on HellaWella.com.
ImmuDyne manufactures and sells proprietary, clinically researched, doctor-recommended, yeast beta-1,3/1,6glucan immune support supplements and topical skin care products. ImmuDyne has a portfolio of unique proprietary and patent-protected products with applications in the wellness, skin care, anti-aging, fitness, and health markets. Immudyne has offices located in Mt. Kisco, NY, and Florence, KY. PURACERE, iNR Start, iNR Strength, iNR Wellness, and iNR Wellness MD are trademarks of ImmuDyne, Inc. Immudyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com.
HellaWella (www.hellawella.com) is a premier provider of consumer health and wellness content. HW's mission is to inspire and encourage healthier living through daily articles, practical tips, and actionable steps encouraging its readers to eat well, exercise in a way that suits their bodies and find more fulfillment and balance in all aspects of their lives.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
CONTACT: Immudyne, Inc. Mark McLaughlin +1-914-714-8901 MarkMcL@immudyne.comSource:Immudyne, Inc.